DSC Investment reduces stake in Genome & Company from 6.53% to 4.30% via CB conversion and open market sales, raising dilution concerns
DSC Investment and its special relations (3 funds) reduced their combined stake in Genome & Company from 6.53% to 4.30%, a decrease of 2.23 percentage points.
The decrease resulted from converting convertible bonds (CB) into common shares at 3,025 won per share on April 28, 2026, followed by open market sales between May 21-27, 2026 at prices ranging from 5,223 to 5,694 won, realizing profits.
Due to the CB conversion and other factors, total outstanding shares increased from 42,106,021 to 54,451,812 (approximately 29% increase), diluting existing shareholders' equity value.
DSC Investment stated the holding purpose is simple investment, not for influencing management.
[AI Comprehensive Analysis]The stake reduction and CB conversion by major shareholder DSC Investment increase share supply, potentially pressuring the stock price in the short term. While dilution is unavoidable for existing shareholders, the VC's profit-taking is a typical exit process.